What happened with HSIC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Dental practices, laboratories, physician practices and outpatient care facilities buy the supplies they need from Henry Schein. The company purchases branded and own-brand products, holds inventory and fills orders through its distribution centers. This distribution business accounts for most revenue: dental supplies and equipment are the largest part, with medical products also substantial. It also earns revenue from equipment installation, repair and other practice services.
Beyond distribution, Henry Schein develops and manufactures specialty products such as dental implants and orthodontic products. It also sells practice-management software and related services that help providers manage patient records, billing and their businesses. These activities contribute a smaller share of sales than distribution.
The distribution business depends on product availability from outside suppliers, generally without long-term supply contracts, and on third-party delivery services to get orders to customers promptly. Selling and distributing pharmaceuticals and medical devices requires licenses and compliance with rules for storage, handling, records and product reporting; noncompliance can restrict sales or lead to loss of licenses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Henry Schein’s core dental-distribution results hinge on dental-practice purchasing and competition with Patterson Dental and Benco Dental, neither of which appears in this list.
Dentsply Sirona supplies dental products that Henry Schein resells to dental practices, but also competes with its own implants and tissue-regeneration materials. Henry Schein accounted for 13% of Dentsply Sirona’s net sales in 2025, making sales through this customer a useful measure of their distribution tie.
Envista supplies dental products to Henry Schein for resale to dental practices, while competing with its specialty business in implants, biomaterials and orthodontics. Henry Schein accounted for approximately 12% of Envista’s 2025 sales, versus 10% in both 2024 and 2023, showing Envista’s growing reliance on this customer.
Medline competes with Henry Schein for physician offices, surgery centers and other healthcare providers buying medical-surgical supplies. Watch its agreements to serve as a provider’s main supplier: these are contracts both distributors compete to win.
McKesson competes with Henry Schein to sell medical products to healthcare providers. Its competition for contracts to be providers’ main medical-surgical supplier is more relevant to Henry Schein than McKesson’s broader drug-distribution business.
Cardinal Health competes with Henry Schein to supply physician offices and surgery centers with medical-surgical products, and both deliver chronic-care supplies to patients at home. Cardinal’s medical-products distribution and at-Home Solutions businesses are the lines to watch for this overlap.
Weave competes with Henry Schein for dental and other healthcare practices buying software to communicate with patients, attract business and collect payments. Its dental-practice customer business is the clearest place to watch this rivalry, rather than its optometry or veterinary customers.
Accendra Health competes with Henry Schein in delivering diabetes and other chronic-condition supplies directly to patients at home, with Accendra paid by health plans, government programs, insurers, agencies and patients. Its diabetes-supply business is the clearest overlap with Henry Schein’s home-care offering, which includes continuous glucose monitoring products.
Fed Interest Rate Decision
The Fed’s decision on its policy rate matters to Henry Schein because higher rates can raise what it pays to borrow on its floating-rate credit lines and receivables facility.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can increase interest paid on the revolving credit agreement, receivables securitization facility and short-term bank lines, leaving less of the distribution business’s earnings after borrowing costs; much of the term loan is hedged.
If it comes in below expectations
Lower rates can reduce interest paid on those floating-rate borrowings, easing borrowing costs for the distribution business; much of the term loan is hedged, so its cost is less directly affected.
Henry Schein Inc earningsThis company
Henry Schein’s report will show whether growth in dental and medical distribution can offset pressure on its profit margin from promotions and product mix.
Read distribution sales growth alongside gross margin—the share of sales left after the cost of goods. Growth with a steady margin means Henry Schein is moving more products without giving up its profit per sales dollar; growth with a falling margin means promotions or product mix are eating into that return. The question is whether added sales bring added gross profit.
Medline Inc. earningsMDLN
Medline’s report will show how providers’ demand and contracts for a main medical-surgical supplier are shaping the competition Henry Schein faces for those accounts.
Watch Medline’s main-supplier contract activity alongside medical-surgical sales. More contracts and resilient sales would show providers are still buying and that Henry Schein faces a strong competitor for medical distribution accounts; weaker activity would point to softer demand or less competitive pressure, not prove how Henry Schein itself performed.
Envista Holdings Corporation earningsNVST
Envista’s report will show whether its dental products sold through Henry Schein hold up, while also shedding light on their competition in implants and related materials.
Separate Envista’s sales to Henry Schein from sales of its own products. Steady sales through Henry Schein would support the supplier-distributor link; a decline could reflect weaker demand or a channel shift. Stronger Envista implant and biomaterial sales would signal tougher competition for Henry Schein’s specialty products, but Envista’s figures alone do not establish Henry Schein’s purchases or sales.
Weave Communications, Inc. earningsWEAV
Weave Communications’ report will show demand among dental practices for patient-communication and payment software, a market where Henry Schein also offers technology products.
Watch growth in Weave’s dental-practice business and whether practices keep adopting its software. Strength would show that practices are still paying for communication, patient acquisition and payment tools, supporting demand in a market Henry Schein also serves; weakness would suggest that spending may be cooling, but would not reveal which vendor won the business.
